We are live on
!
Find out more
VC
Vivo Capital Portfolio holdings
AUM
$1.2B
1-Year Est. Return
911.44%
This Fund
S&P 500
This Quarter
Est. Return
+32.03%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$977M
AUM Growth
+$222M
(+29%)
Cap. Flow
+$54.3M
Cap. Flow
% of AUM
5.56%
Top 10 Holdings %
Top 10 Hldgs %
75%
Holding
45
New
5
Increased
5
Reduced
5
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SVA
Sinovac Biotech, Ltd
SVA
|
+$38.2M |
| 2 |
CDTX
Cidara Therapeutics
CDTX
|
+$15.1M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$10.6M |
| 4 |
DBVT
DBV Technologies
DBVT
|
+$9.33M |
| 5 |
CytomX Therapeutics
CTMX
|
+$9.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLNO
Soleno Therapeutics
SLNO
|
+$37.4M |
| 2 |
Instil Bio
TIL
|
+$6.12M |
| 3 |
RGLS
Regulus Therapeutics
RGLS
|
+$4.72M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$3.36M |
| 5 |
Delcath Systems
DCTH
|
+$2.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Celcuity
CELC
$4.21B
| $8.15M | 0.83% |
610,500
| – | – |
|
27
Cogent Biosciences
COGT
$6.65B
| $8.06M | 0.82% |
1,122,471
| – | – |
|
|
28
Delcath Systems
DCTH
$422M
| $7.75M | 0.79% |
569,526
-180,669
| -24% | -$2.52M |
|
29
Praxis Precision Medicines
PRAX
$8.58B
| $7.05M | 0.72% |
+167,600
| New | +$6.38M |
|
|
DRUG
30
Bright Minds Biosciences
DRUG
$719M
| $6.57M | 0.67% |
251,572
| – | – |
|
31
Olema Pharmaceuticals
OLMA
$1B
| $6.41M | 0.66% |
1,505,862
| – | – |
|
|
SLN
32
Silence Therapeutics
SLN
$495M
| $6.41M | 0.66% |
1,105,454
| – | – |
|
33
Verastem
VSTM
$510M
| $6.38M | 0.65% |
1,538,461
| – | – |
|
|
34
Instil Bio
TIL
$48.3M
| $6.1M | 0.62% |
292,743
-292,742
| -50% | -$6.12M |
|
35
Unicycive Therapeutics
UNCY
$137M
| $5.42M | 0.56% |
1,137,015
| – | – |
|
36
Sera Prognostics
SERA
$79.9M
| $4.57M | 0.47% |
1,650,440
| – | – |
|
|
ETNB
37
DELISTED
89bio
ETNB
| $3.7M | 0.38% |
376,804
| – | – |
|
38
Tango Therapeutics
TNGX
$4.43B
| $3.07M | 0.31% |
+600,000
| New | +$1.48M |
|
39
Surrozen
SRZN
$258M
| $2.32M | 0.24% |
260,000
| – | – |
|
40
Tenax Therapeutics
TENX
$363M
| $1.2M | 0.12% |
208,333
| – | – |
|
41
Bolt Biotherapeutics
BOLT
$7.67M
| $986K | 0.1% |
176,064
-1
| -0% | -$7 |
|
42
Precision BioSciences
DTIL
$180M
| $19.6K | ﹤0.01% |
4,675
| – | – |
|
43
Aligos Therapeutics
ALGS
$26.2M
| – | – |
-10,199
| Closed | -$84.1K |
|
|
ALLK
44
DELISTED
Allakos
ALLK
| – | – |
-765,500
| Closed | -$174K |
|
|
RGLS
45
DELISTED
Regulus Therapeutics
RGLS
| – | – |
-2,696,426
| Closed | -$4.72M |
|
Similar funds
SGDR
FCCPG
AIM
CA
SC
HCM
MB
CCM
Vivo Capital's Q2 2025 Portfolio in Review
As of Q2 2025, Vivo Capital held 45 positions worth $977M, up 29% from $755M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Vivo Capital deployed $54.3M of net new capital in Q2 2025, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was Sinovac Biotech, Ltd: 5,903,000 shares worth $38.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Soleno Therapeutics, an estimated $37.4M trimmed.
- Vivo Capital's largest Q2 2025 buy was Sinovac Biotech, Ltd: 5,903,000 shares worth $38.2M.
- Vivo Capital added most to Cidara Therapeutics in Q2 2025, an estimated $15.1M increase.
- Vivo Capital's biggest Q2 2025 reduction was Soleno Therapeutics, cutting an estimated $37.4M.
- Vivo Capital fully exited Regulus Therapeutics in Q2 2025, selling an estimated $4.72M.
- Vivo Capital's ten largest holdings make up 75% of its $977M portfolio in Q2 2025.
- Vivo Capital opened 5 new positions and closed 3 in Q2 2025.
- Vivo Capital's portfolio value rose 29% quarter-over-quarter to $977M.
Based on Vivo Capital's 13F filing for Q2 2025, filed 14 Aug 2025.